These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 6139115)

  • 21. Metric characteristics of the drug-induced extrapyramidal symptoms scale (DIEPSS): a practical combined rating scale for drug-induced movement disorders.
    Kim JH; Jung HY; Kang UG; Jeong SH; Ahn YM; Byun HJ; Ha KS; Kim YS
    Mov Disord; 2002 Nov; 17(6):1354-9. PubMed ID: 12465082
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Legal liability with psychotropic drug use: extrapyramidal syndromes and tardive dyskinesia.
    Mills MJ; Eth S
    J Clin Psychiatry; 1987 Sep; 48 Suppl():28-33. PubMed ID: 3624218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interpatient variations in antipsychotic therapy.
    McIntyre IM; Gershon S
    J Clin Psychiatry; 1985 May; 46(5 Pt 2):3-5. PubMed ID: 2859279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vulnerability to extrapyramidal side effects.
    Van Putten T
    Clin Neuropharmacol; 1983; 6 Suppl 1():S27-34. PubMed ID: 6139164
    [No Abstract]   [Full Text] [Related]  

  • 25. Review of incidence studies of tardive dyskinesia associated with typical antipsychotics.
    Glazer WM
    J Clin Psychiatry; 2000; 61 Suppl 4():15-20. PubMed ID: 10739326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathophysiology of antipsychotic drug-induced movement disorders.
    Casey DE
    J Clin Psychiatry; 2004; 65 Suppl 9():25-8. PubMed ID: 15189109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Testing basic visual functions in the evaluation of extrapyramidal side effects of antipsychotic agents].
    Kéri S; Antal A; Szekeres G; Szendi I; Kovács Z; Janka Z; Benedek G
    Orv Hetil; 1998 Feb; 139(5):235-8. PubMed ID: 9489377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical relationship of extrapyramidal symptoms and tardive dyskinesia.
    Andrew HG
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S76-80. PubMed ID: 7874668
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The clinical use of antipsychotic medications.
    Coyle JT
    Med Clin North Am; 1982 Sep; 66(5):993-1009. PubMed ID: 6127455
    [No Abstract]   [Full Text] [Related]  

  • 30. Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy.
    Crescenti A; Mas S; Gassó P; Parellada E; Bernardo M; Lafuente A
    Clin Exp Pharmacol Physiol; 2008 Jul; 35(7):807-11. PubMed ID: 18346175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Motor and mental side effects of clozapine.
    Gerlach J; Peacock L
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():107-9. PubMed ID: 7961551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders.
    Ganzini L; Casey DE; Hoffman WF; McCall AL
    Arch Intern Med; 1993 Jun; 153(12):1469-75. PubMed ID: 8512437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sorting through EPS (extrapyramidal symptoms).
    Blair DT
    Geriatr Nurs; 1991; 12(5):244-6. PubMed ID: 1687319
    [No Abstract]   [Full Text] [Related]  

  • 34. Efficacy of propranolol in a patient with tardive dyskinesia and extrapyramidal syndrome.
    Chaudhry R; Radonjic D; Waters B
    Am J Psychiatry; 1982 May; 139(5):674-6. PubMed ID: 6122382
    [No Abstract]   [Full Text] [Related]  

  • 35. The efficacy, safety, and tolerability of antipsychotics in the elderly.
    Maixner SM; Mellow AM; Tandon R
    J Clin Psychiatry; 1999; 60 Suppl 8():29-41. PubMed ID: 10335669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia.
    Keck PE; McElroy SL; Strakowski SM; Soutullo CA
    J Clin Psychiatry; 2000; 61 Suppl 4():33-8. PubMed ID: 10739329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phenomenological differences between spontaneous and drug-related extrapyramidal syndromes in patients with schizophrenia-spectrum disorders.
    Peralta V; de Jalón EG; Campos MS; Cuesta MJ
    J Clin Psychopharmacol; 2013 Jun; 33(3):438-40. PubMed ID: 23609391
    [No Abstract]   [Full Text] [Related]  

  • 38. [Extrapyramidal side effects of neuroleptic and antidepressant treatment: assessment of potential risk factors through CYP2D6 genetic polymorphism].
    Reggiani K; Vandel P; Haffen E; Sechter D; Bizouard P; Vandel S
    Encephale; 2000; 26(1):62-7. PubMed ID: 10875063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lack of extrapyramidal side effects predicts quality of life in outpatients treated with clozapine or with typical antipsychotics.
    Strejilevich SA; Palatnik A; Avila R; Bustin J; Cassone J; Figueroa S; Gimenez M; de Erausquin GA
    Psychiatry Res; 2005 Feb; 133(2-3):277-80. PubMed ID: 15741003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Extrapyramidal motor side-effects and blood profile changes. Stumbling blocks in psychiatric pharmacotherapy].
    Grohmann R; Hippius H; Rüther E
    MMW Fortschr Med; 2001 May; 143 Suppl 2():76-7. PubMed ID: 11434265
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.